Non-small cell lung cancer
Researchers at Nanchang University have made a significant breakthrough in the diagnosis of non-small cell lung cancer (NSCLC) by developing a non-invasive method to predict epidermal growth factor receptor (EGFR) gene mutations. This method uses multi-parameter CT perfusion imaging (CTPI) to analyze blood volume, transit time, and perfusion surface in
Cancer research
Researchers at Nanchang University have made a significant breakthrough in the diagnosis of non-small cell lung cancer (NSCLC) by developing a non-invasive method to predict epidermal growth factor receptor (EGFR) gene mutations. This method uses multi-parameter CT perfusion imaging (CTPI) to analyze blood volume, transit time, and perfusion surface in
Cancer research
Research conducted at the Gansu University of Chinese Medicine in People's Republic of China has led to a potential breakthrough in the treatment of non-small cell lung cancer (NSCLC). The study, published in the journal Frontiers in Oncology, investigates the benefits and risks of combining Fuzheng Yiliu Decoction,
Cancer research
Research conducted by Qingdao Municipal Hospital in Shandong, People's Republic of China, has shown that combining radiotherapy with anti-angiogenic therapy, immune checkpoint inhibitors, and chemotherapy can be effective in prolonging the survival of patients with advanced non-small cell lung cancer (NSCLC). The study, published in Frontiers in Oncology,
Cancer research
A recent study published in the American Journal of Clinical Oncology has found that adjuvant alectinib is a more effective and cost-effective treatment option compared to platinum-based chemotherapy for patients with resectable (stage IB to IIIA) ALK+ non-small cell lung cancer. The study, conducted by researchers at Genentech Inc., evaluated
Cancer metastasis
Research published in the World Journal of Surgical Oncology has detailed a rare case of rectal metastasis from an EGFR L858R-mutant primary lung adenocarcinoma. The study describes a 79-year-old male patient who presented with worsening constipation, which led to the discovery of a rectal mass. Initial biopsies revealed chronic rectal
Cancer research
Research conducted by scientists at Bengbu Medical University has shed new light on the role of long non-coding RNA (lncRNA) FEZF1-AS1 in non-small cell lung cancer (NSCLC) tumorigenesis and ferroptosis. The study found that FEZF1-AS1 promotes NSCLC progression through suppressing ferroptosis by activating the tumor necrosis factor-alpha (TNF-a)/nuclear factor-kappa
Non-small cell lung cancer
Research conducted by Qingdao Municipal Hospital in Shandong, People's Republic of China, has shown that combining radiotherapy with anti-angiogenic therapy, immune checkpoint inhibitors, and chemotherapy can be effective in prolonging the survival of patients with advanced non-small cell lung cancer (NSCLC). The study, published in Frontiers in Oncology,
Non-small cell lung cancer
Research conducted by investigators at the Shanghai University of Traditional Chinese Medicine has yielded new insights into the treatment of non-small cell lung cancer (NSCLC). The study, published in the Journal of Ethnopharmacology, demonstrates the therapeutic potential of Wu-Wei-Zi decoction (WWZ) in modulating the tumor immune microenvironment (TIME) and inhibiting
Non-small cell lung cancer
Research conducted at the Gansu University of Chinese Medicine in People's Republic of China has led to a potential breakthrough in the treatment of non-small cell lung cancer (NSCLC). The study, published in the journal Frontiers in Oncology, investigates the benefits and risks of combining Fuzheng Yiliu Decoction,
Non-small cell lung cancer
Research published in the World Journal of Surgical Oncology has detailed a rare case of rectal metastasis from an EGFR L858R-mutant primary lung adenocarcinoma. The study describes a 79-year-old male patient who presented with worsening constipation, which led to the discovery of a rectal mass. Initial biopsies revealed chronic rectal
Biochemistry
Researchers from the Boonshoft School of Medicine have made a significant discovery in the treatment of non-small cell lung cancer (NSCLC). By combining immune checkpoint inhibitors (ICIs) and anti-angiogenic pharmacologic agents, they have shown promising results in patients with NSCLC. This breakthrough has the potential to offer a new therapeutic
